January 21, 2017 12:51 AM ET

Healthcare Equipment and Supplies

Company Overview of Medinol Ltd.

Company Overview

Medinol Ltd. engages in the research, development, manufacture, and marketing of cardiovascular intervention solutions. It offers bare metal stents and elastomer-based drug-eluting stents. The company was founded in 1992 and is based in Tel Aviv, Israel.

Building 8

35th Floor

Kiryat Atidim

POB 58165

Tel Aviv,  6158101


Founded in 1992


972 3 767 9000


972 3 648 2310

Key Executives for Medinol Ltd.

Founder, Chief Executive Officer and Director
Age: 69
Founder, Chairman and Chief Technology Officer
Age: 71
Vice President of Finance
Vice President of Human Resource and Infrastructure
Vice President of Innovative Technologies
Compensation as of Fiscal Year 2016.

Medinol Ltd. Key Developments

Medinol Announces Excellent Clinical Results for EluNIR™

Medinol announced excellent twelve month clinical results from the BIONICS study.  The study was conducted to evaluate EluNIR™, Medinol's novel coronary stent system and the first ever elastomer coated drug eluting stent (eDES™). This global pivotal study enrolled 1,919 patients from 76 sites in 8 countries. The BIONICS results were highlighted in the opening Late Breaking Trial session of the 28th annual Transcatheter Cardiovascular Therapeutics (TCT2016) scientific symposium in Washington DC. The study data will be submitted to the FDA to support the U.S. regulatory approval of EluNIR for the treatment of patients with narrowing or blockage of their coronary arteries. The BIONICS study, a global, prospective, randomized, multicenter, non-inferiority clinical trial was designed to include a 'more comers' population, i.e. one that closely represents the real-world patient population. The EluNIR Stent (study name BioNIR™) was compared to the Resolute Integrity™ Stent (1:1 randomization). Key results from the study include: For its primary endpoint, Target Lesion Failure (TLF), EluNIR demonstrated a rate of 5.4% at 12 months compared to an identical rate of 5.4% for Resolute (p=0.0013 for non-inferiority). TLF was defined as the composite of cardiac death, target vessel MI, and clinically driven TLR; and Good safety profile, with a low definite/probable stent thrombosis rate of 0.4% for EluNIR, compared to 0.8% for Resolute (p=NS) with no events beyond 30 days for EluNIR. In addition to the BIONICS study, new twelve month data from NIREUS, the European pivotal trial for EluNIR, were presented at TCT. The NIREUS study, a prospective, multi-center, randomized, non-inferiority pivotal study comparing EluNIR to the Resolute Integrity Stent, met its non-inferiority primary end point of angiographic in-stent late loss at 6 months. These data were presented at EuroPCR in May 2016. The recent twelve month clinical data, presented TLF of 3.4% for EluNIR and 5.9% for Resolute (p=NS).These outcomes were consistent with the positive results of BIONICS.

Medinol Ltd. Presents at Life Sciences Israel(TM) 2015, Feb-18-2015 10:15 AM

Medinol Ltd. Presents at Life Sciences Israel(TM) 2015, Feb-18-2015 10:15 AM. Venue: Dan Panorama Hotel, Charles Clore Park, Tel Aviv 68012, Israel. Speakers: Hillegonda Groen, Vice President Marketing & Sales Europe.

Similar Private Companies By Industry

Company Name Region
2P2D Solutions Ltd. Middle East/Africa
A.B. Dental Devices, Limited Middle East/Africa
ActiVein Inc. Middle East/Africa
Acuity Ltd. Middle East/Africa
ADM Advanced Dialysis Methods Ltd. Middle East/Africa

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Medinol Ltd., please visit www.medinol.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.